CO6231056A2 - Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas - Google Patents

Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas

Info

Publication number
CO6231056A2
CO6231056A2 CO09111661A CO09111661A CO6231056A2 CO 6231056 A2 CO6231056 A2 CO 6231056A2 CO 09111661 A CO09111661 A CO 09111661A CO 09111661 A CO09111661 A CO 09111661A CO 6231056 A2 CO6231056 A2 CO 6231056A2
Authority
CO
Colombia
Prior art keywords
hsa
patient
expression
treatment
post
Prior art date
Application number
CO09111661A
Other languages
English (en)
Spanish (es)
Inventor
Jian-Wei Chen
Sung-Liang Yu
Hsuan-Yu Chen
Gee-Chen Chang
Chih-Yi Chen
Pan-Chyr Yang
Original Assignee
Univ Nat Taiwan
Dcb Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Taiwan, Dcb Usa Llc filed Critical Univ Nat Taiwan
Publication of CO6231056A2 publication Critical patent/CO6231056A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO09111661A 2007-04-10 2009-10-08 Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas CO6231056A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91099307P 2007-04-10 2007-04-10

Publications (1)

Publication Number Publication Date
CO6231056A2 true CO6231056A2 (es) 2010-12-20

Family

ID=39831416

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09111661A CO6231056A2 (es) 2007-04-10 2009-10-08 Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas

Country Status (13)

Country Link
US (1) US7745134B2 (enExample)
EP (1) EP2134874A4 (enExample)
JP (1) JP2010523156A (enExample)
KR (1) KR20100027102A (enExample)
CN (1) CN101688240A (enExample)
AU (1) AU2008237036A1 (enExample)
CA (1) CA2695868A1 (enExample)
CO (1) CO6231056A2 (enExample)
IL (1) IL201298A0 (enExample)
MX (1) MX2009010899A (enExample)
RU (1) RU2009141359A (enExample)
TW (1) TWI367949B (enExample)
WO (1) WO2008124777A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103866018B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CN103028120B (zh) 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2524018T3 (es) 2006-01-05 2014-12-03 The Ohio State University Research Foundation Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
CA2657030A1 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
JP5501766B2 (ja) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン
US8034560B2 (en) 2007-01-31 2011-10-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
CA2690144A1 (en) * 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
AU2008283997B2 (en) 2007-08-03 2014-04-10 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
CN101836112A (zh) 2007-08-22 2010-09-15 俄亥俄州立大学研究基金会 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
AU2009257410B2 (en) 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
US8729041B2 (en) 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
EP2196543A1 (en) * 2008-12-15 2010-06-16 Koninklijke Philips Electronics N.V. Compositions and methods for micro-rna expression profiling of hepatocellular cancer
WO2010094155A1 (en) * 2009-02-23 2010-08-26 Capitalbio Corporation Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival
CN101638656B (zh) * 2009-08-28 2011-05-11 南京医科大学 一种与非小细胞肺癌预后相关的血清/血浆miRNA标志物及其应用
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
JP5763098B2 (ja) * 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US20110223607A1 (en) 2010-03-12 2011-09-15 Quest Diagnostics Investments Incorporated Circulating microrna as a marker for hepatocellular carcinoma
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
US8404437B2 (en) 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer
US20140113978A1 (en) * 2011-05-01 2014-04-24 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
EP2757154A4 (en) 2011-09-16 2015-10-14 Lsip Llc METHOD FOR DETECTING BLOOD TUMOR CELLS, PRIMER FOR USE IN THIS METHOD FOR DETECTING BLOOD TUMOR CELLS AND BLADDER CANCER MARKERS
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
US9850541B2 (en) * 2011-12-19 2017-12-26 Valley Health System Methods and kits for detecting subjects at risk of having cancer
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
US10738363B2 (en) 2016-08-31 2020-08-11 National Central University Analyzer and analytical method for predicting prognosis of cancer radiotherapy
DE102018110526A1 (de) 2018-05-02 2019-11-07 Faurecia Autositze Gmbh Verfahren zur Montage eines Linearaktuators für einen Kraftfahrzeugsitz
CN108630317B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肝癌个性化预后评估方法
CN108320806B (zh) * 2018-05-09 2022-04-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的结肠癌个性化预后评估方法
CN108647493B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种肾透明细胞癌个性化预后评估方法
CN108470111B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胃癌个性化预后评估方法
CN108611416B (zh) * 2018-05-09 2020-12-29 中国科学院昆明动物研究所 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法
CN108733980B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 基于多基因表达特征谱胶质母细胞瘤个性化预后评估方法
CN108648826B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法
CN108363907B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
US11410745B2 (en) * 2018-06-18 2022-08-09 International Business Machines Corporation Determining potential cancer therapeutic targets by joint modeling of survival events
TWI758670B (zh) * 2018-12-24 2022-03-21 奎克生技光電股份有限公司 健康風險評估方法
CN111172285A (zh) * 2020-02-26 2020-05-19 江南大学附属医院 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用
TWI878107B (zh) * 2024-04-30 2025-03-21 朱旆億 乳癌預後存活率預測模型建立方法及系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029287A2 (en) * 2002-09-27 2004-04-08 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
US20040152112A1 (en) * 2002-11-13 2004-08-05 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
CA2554818A1 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
US20050272067A1 (en) * 2004-03-10 2005-12-08 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20060078913A1 (en) * 2004-07-16 2006-04-13 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling

Also Published As

Publication number Publication date
US20080254473A1 (en) 2008-10-16
US7745134B2 (en) 2010-06-29
AU2008237036A2 (en) 2010-09-09
WO2008124777A1 (en) 2008-10-16
CN101688240A (zh) 2010-03-31
IL201298A0 (en) 2010-05-31
KR20100027102A (ko) 2010-03-10
AU2008237036A1 (en) 2008-10-16
EP2134874A1 (en) 2009-12-23
TWI367949B (en) 2012-07-11
EP2134874A4 (en) 2010-12-22
TW200912002A (en) 2009-03-16
RU2009141359A (ru) 2011-05-20
MX2009010899A (es) 2010-02-17
JP2010523156A (ja) 2010-07-15
CA2695868A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
CO6231056A2 (es) Prediccion de la supervivencia al pos-tratamiento en pacientes de cancer con micro-rnas
Chen et al. Drug resistance‐related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies
Li et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance
US9745630B2 (en) MiRNA fingerprint in the diagnosis of prostate cancer
MX2010004916A (es) Proceso para predecir el pronostico de cancer en celulas escamosas de pulmon.
ES2721639T3 (es) Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
EA201171335A1 (ru) Вектор гена
MY161199A (en) Fused tricyclic dual inhibitors of cdk 4/6 and flt3
EA202190474A1 (ru) Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
EA024630B9 (ru) Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac)
WO2009012468A3 (en) Differential expression of micrornas in nonfailing versus failing human hearts
RU2014117666A (ru) Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами атr
Wang et al. miRNA‐194 predicts favorable prognosis in gastric cancer and inhibits gastric cancer cell growth by targeting CCND1
BR112016029781A2 (pt) composições e métodos para inibir a expressão de gene de alfa-1 antitripsina
PE20140647A1 (es) Metodo para tratamiento de cancer de pulmon de celulas no pequenas
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
CR20110479A (es) Combinaciones farmaceuticas que comprenden rdea 119/bay 869766 para el tratamiento de canceres especificos
Bao et al. MiR-96 expression in prostate cancer and its effect on the target gene regulation.
Venza et al. Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines
Chai et al. Clinical implications of microRNAs in liver cancer stem cells
Guo et al. miR-181b as a potential molecular target for anticancer therapy of gastric neoplasms
TW200738253A (en) Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
MX2021009184A (es) Métodos para tratar cáncer de próstata basado en subtipos moleculares.

Legal Events

Date Code Title Description
FA Application withdrawn